» » Plagiarists at ZS Genetics Confirmed and Use My Sequencing Inventions
Информация к новости
  • Просмотров: 1150
  • Автор: admin
  • Дата: 20-01-2014, 21:51
20-01-2014, 21:51

Plagiarists at ZS Genetics Confirmed and Use My Sequencing Inventions

Category: Blogs

Plagiarists at ZS Genetics Confirmed and Use My Sequencing Inventions

Alexander Cherkasky

alexcherkasky@googlemail.com

http://feasibilityofalexandercherkaskysinven.blogspot.de/


ZS Genetics’ claimed technology comprises long-read, single molecule
DNA sequencing technology, with extremely long read-length and
single-molecule sampling, as well as labeling DNA and sequencing by
electron microscopy. DNA sequence is prepared and
linearized/stretched. The substrate is preferably transparent.
My prior patent publications disclose:

1. Sequencing by microscopy, especially electron microscopy (using an
electron microscope) or other physico-optical methods (DE19937512 A1
(filed on August 09, 1999 and published on February 15, 2001), (see
Abstract; column 1, line 68; column 3, line 55 and claim 2),
DE19937512 B4 (0009, 0018 and claim 1), DE19929530 A1 (filed on June
28, 1999 and published on January 04, 2001), (Abstract; column 1, line
64; column 2, line 54; column 3, line 68; column 4, line 4 and claim
16), DE19929530 B4 (0006, 0013 and 0024)),
2. Sample preparation including degradation of chromosomes,
preparation and fixing of DNA sequence (long, very long or extremely
long single molecule DNA sequence(s)) to the (long) substrate, (with
or without DNA modification), DNA stretching (and immobilization) on
the substrate, (extremely long read-length and single-molecule
sampling) for the sequencing by Electron Microscopy (DE19937512 A1
(Abstract, columns 1-7, claims 1, 3-9, 13-15), DE19937512 B4
(0009-0017, 0020-0046 (including lay down DNA sequence from pipette)
as well as claim 1), DE19929530 A1 (columns 2-9), DE19929530 B4
(0007-0022, 0026-0067)),
3. Transparent substrates (DE19937512 A1 (column 2, lines 49-50, as
well as claim 10), DE19937512 B4 (0013), DE19929530 A1 (column 4,
lines 6-9), DE19929530 B4 (0025)),
4. Conversion of (long) double-stranded DNA sequences to
single-stranded DNA sequences, for example by using enzymes
(DE19937512 A1 (column 3, lines 62-68; column 7, lines 1-11; claims 9,
14, 15), DE19937512 B4 (0019, 0043), DE19929530 A1 (claim 26)),
5. Labeling (all labels of nucleic acids, especially DNA, every label
of nucleic acids, especially DNA, and each labeled nucleic acid,
especially DNA, including iodine and bromine labels/labeling, are
covered by my published patent application DE102007027596 A1 (filed on
June 12, 2007, published on January 29, 2009; claims 6, 8, as well as
1 and 4 (use as filter and absorption substances))), and
6. Reading the sequence of long segments of DNA, long-reads of DNA
molecules (individual or single DNA molecules) and automatic and
multiparallel sequencing (DE19937512 A1, (column 3, lines 52-62;
column 6, line 68; column 7, line 1; claims 16, 17 and 18),
DE19937512 B4 (0009, 0018, 0019, 0032 and 0036), DE19929530 A1 (column
8, lines 27-51)).

Thus, it is possible, that through reexaminations with the USPTO the
patents (issued by error of examiners) of ZS Genetics can be
invalidated and patent applications of ZS Genetics can be rejected,
because they are not new and not inventive. In that possible case, ZS
Genetics will not be protected from competitors. Thus, investors will
reduce their expectations, especially because the perspectives of
revenues will be reduced and everybody will be able to use the
results/fruits of the experimental work of ZS Genetics. ZS Genetics
does not disclose this information, especially to investors.
The October 2012 article in Microscopy and Microanalysis (the October
edition of Microscopy and Microanalysis (October 10, 2012)) of
scientists at Harvard University (team led by Professor David Bell, at
the School of Engineering and Applied Sciences and the Center for
Nanoscale Systems at Harvard University), the University of New
Hampshire (Professor Kelly Thomas, Chair of the Hubbard Center for
Genome Studies at the University of New Hampshire) and ZS Genetics
(William Glover, President of ZS Genetics) confirmed feasibility of my
sequencing inventions.
See also http://feasibilityofalexandercherkaskysinven.blogspot.de/ for
more information.